Renske Olie

Academic Staff

Dr Renske Olie studied Medicine at Maastricht University and obtained her MD in 2006. Subsequently, she specialised in Internal Medicine (specialisation vascular medicine) in Tilburg and Maastricht UMC+. Currently, she works as an internist at the Department of Internal Medicine and the Thrombosis Expertise Center (TEC) at the MUMC+ Heart+Vascular Center, where she started an outpatient clinic for high-risk patients on dual/triple antithrombotic therapy.

Since 2013, she has been involved in scientific research at CARIM. Her research focusses on the safety of antithrombotic strategies in high-risk patients with atherothrombotic disease, and the value of several laboratory tests in the risk assessment of these patients.

 

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.334
T: +31(0)43 387 50 05

  • 2019
    • Petersohn, S., Ramaekers, B. L. T., Olie, R. H., ten Cate-Hoek, A. J., Daemen, J-W. H. C., ten Cate, H., & Joore, M. A. (2019). Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. Quality of Life Research, 28(8), 2257-2279. https://doi.org/10.1007/s11136-019-02166-0
    • Olie, R. H., van der Meijden, P. E. J., Spronk, H. M. H., van Oerle, R., Barvik, S., Bonarjee, V. V. S., Ten Cate, H., & Nilsen, D. W. T. (2019). Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease. TH open : companion journal to thrombosis and haemostasis, 3(3), e259-e262. https://doi.org/10.1055/s-0039-1695710
  • 2018
    • ten Cate, H., Olie, R. H., ten Cate-Hoek, A. J., & Henskens, Y. M. C. (2018). Direct oral anticoagulants: When to consider laboratory testing?International Journal of Laboratory Hematology, 40(S1), 30-33. https://doi.org/10.1111/ijlh.12816
    • Olie, R. H., van der Meijden, P. E. J., & ten Cate, H. (2018). The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Research and practice in thrombosis and haemostasis, 2(2), 188-198. https://doi.org/10.1002/rth2.12080
    • Spronk, H. M. H., Padro, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G., d'Alessandro, E., Wenzel, P., Coenen, D. M., Reitsma, P. H., Ruf, W., van Gorp, R. H., Koenen, R. R., Vajen, T., Alshaikh, N. A., Wolberg, A. S., Macrae, F. L., ... ten Cate, H. (2018). Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 118(2), 229-250. https://doi.org/10.1160/TH17-07-0492
  • 2017
    • Olie, R. H., Meertens, N. E. L., Henskens, Y. M. C., & ten Cate, H. (2017). Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels. The Nephron Journals, 137(2), 113-123. https://doi.org/10.1159/000477474
    • Vries, M. J. A., Bouman, H. J., Olie, R. H., Veenstra, L. F., Zwaveling, S., Verhezen, P. W. M., ten Cate-Hoek, A. J., ten Cate, H., Henskens, Y. M. C., & van der Meijden, P. E. J. (2017). Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. European Heart Journal-Cardiovascular Pharmacotherapy, 3(1), 11-17. https://doi.org/10.1093/ehjcvp/pvw026